


**NEW**

# ATREVIA<sup>®</sup> XR

**3 MONTHS**

FLURALANER



## INTRODUCING AN IRRESISTIBLE PROTECTION



EXCLUSIVE FOR DOGS



Ectoparasiticide against  
fleas, ticks and mites in  
soft chews.

**PROTECTION FOR  
3 MONTHS**



FLEAS



TICKS



MITES

# ATREVIA® XR, 3 MONTHS OF IRRESISTIBLE PROTECTION

🐕 FLEAS | 🦋 TICKS | 🦠 SCABIES MITES



## FLURALANER FOR QUARTERLY ADMINISTRATION

Fluralaner is a new generation compound belonging to the isoxazoline family. This molecule is rapidly absorbed and distributed, providing greater efficacy compared to phenylpyrazoles (fipronil), neonicotinoids (imidacloprid), pyrethroids (permethrin), macrocyclic lactones (ivermectin), among others.

## FLURALANER, PREMIUM ACTIVE INGREDIENT ZERO RESISTANCE

**We innovate in the use of fluralaner to give you the freedom to choose the most convenient treatment. Choose between: ATREVIA® ONE for 1 month of protection or ATREVIA® XR for 3 months.**

- NON - RESISTANCE
- FAST ACTION
- DELICIOUS TASTE
- BROAD - SPECTRUM
- MONTHLY OR QUARTERLY DOSAGE
- ENVIRONMENTAL CONTROL

## ATREVIA® XR



Weight presentation	Mini 2-4.5 kg	Small 4.5-10 kg	Medium 10-20 kg	Large 20-40 kg
FLURALANER (mg per tablet)	125 mg	250 mg	500 mg	1000 mg
Tablet Weight	1 g	2 g	4 g	8 g

For dogs weighing more than 40 kg, administer a suitable combination. The tablets are protected by a unitary sealed aluminum blister. It is recommended to dose with food. Atrevia®XR protects for 3 months.

## BENEFITS

## ATREVIA® XR



### ONE OR THREE MONTHS

Choose the most convenient treatment for your patients. Atrevia® One for monthly protection or Atrevia® XR for 3 months of sustained protection against ectoparasites.



### FAST AND EFFECTIVE

Atrevia® XR acts from the 90th minute against fleas<sup>(1)</sup>, reaching 99% effectiveness at 8 hours after administration<sup>(2)</sup>.



### IRRESISTIBLE PROTECTION

Atrevia® XR has high palatability and acceptance. According to field studies, it has a voluntary consumption of 95.64%<sup>(3)</sup>.



### BROAD SPECTRUM AND ENVIRONMENTAL CONTROL

Atrevia® XR is lethal against fleas, ticks, and scabies mites. Its continuous use helps to control immature stages.



### HEALTHIER SKIN

Complete recovery in cases of scabies, and the perfect complement for the treatment against flea allergy dermatitis (FAD).



### SAFETY

Safe in lactating females, puppies from the 8th week and/or 2 kg of weight, dogs with MDR1 GEN mutation, and other breeds sensitive to macrocyclic lactones<sup>(7)</sup>. No serious adverse reactions or neurological reactions have occurred during the studies<sup>(4)</sup>.



### INNOCUITY


The systemic action of Atrevia® XR allows protection without exposing families to insecticides as in topical formulations.



### WATER-RESISTANT

Due to its administration route, it can be used the same bath day. Its efficacy is not diminished by the contact of the pet with water.

**ATREVIA® XR IS A NEW GREAT-TASTING SOFT TABLET THAT ELIMINATES FLEAS, TICKS, AND MITES QUICKLY, EFFECTIVELY AND SAFELY FOR 3 MONTHS.**






## ATREVIA® XR STARTS TO WORK AFTER 90 MINUTES <sup>(1)</sup>. FIELD STUDIES UNDER REAL CONDITIONS PROVE THEIR EFFECTIVENESS

### Fleas Immediate and prolonged action



Atrevia® XR rapidly eliminates fleas within 90 minutes of administration. It is effective against *Ctenocephalides felis* and *Ctenocephalides canis* infestations. It provides environmental control, avoiding reinfestations.



#### Performance in Fleas


Atrevia® XR exhibits lethal activity for at least 98 days against fleas. This contributes to a better environmental control, maintaining the same activity as the reference product on the market <sup>(2)</sup>.

Performance  
Atrevia® XR ■ Other ■

### Ticks An enemy with the hours counted



Atrevia® XR has action against adult and immature form of *Rhipicephalus sanguineus*, *Ixodes* spp. and *Dermacentor reticulatus* and *Dermacentor variabilis*. Its use prevents vector-borne diseases, such as ehrlichiosis, babesiosis, anaplasmosis and others.



#### Performance in Ticks


Atrevia® XR maintains persistent activity for up to 14 weeks (day 98) against ticks. Studies support the effectiveness of Atrevia® in comparison with other reference products on the market <sup>(5)</sup>.

Performance  
Atrevia® XR ■ Other ■

### Mites An end to scabies




Atrevia® XR is great for the control of dermatological problems caused by *Demodex canis*, *Sarcoptes scabiei var. canis* and *Otodectes cynotis*. Our field studies support its effectiveness in controlling the associated clinical signs: plaques, scales, crusts, comedones, papules, pustules, alopecia and erythema.



#### Demodectic mange

A single dose of Atrevia® XR allowed the resolution of 100% of demodicosis cases from day 42, after administration <sup>(6)</sup>.



#### Sarcoptic mange

Atrevia® XR achieved 90 % effectiveness on day 98 after administration. Most cases of scabies can be resolved with a single dose <sup>(6)</sup>.

# PROTECTION PROVEN BY FIELD STUDIES UNDER REAL-LIFE CONDITIONS

## ATREVIA® XR

### HIGH PALATABILITY

Atrevia® has a high palatability and acceptance. According to field studies, it has a voluntary consumption of 98 % <sup>(3)</sup>.

Score	Quantity	Percentage
0	8	1.11%
1	7	0.97%
2	12	1.67%
3	693	96.25%



Score: **0** Animal should be forced to eat the tablet **1** Animal shows interest initially, but should be forced to eat the tablet **2** Animal shows interest and eats the tablet when it is placed on its snout **3** Animal smells the tablet and eats it voluntarily

### QUICK ACTION ONSET

Atrevia® XR starts to eliminate fleas from the 90th minute <sup>(1)</sup> after administration. The table describes the progression during the first 4 action hours of the product. The baseline count is given for reference.

	Baseline Count	90'	120'	180'	240'	Start of activity Average: 91' Range: 88' - 98'
Mean (Average)	185 (179)	0.83(1)	9.83(9.5)	30(29.5)	84(89.5)	
Count Range	95-261	0-2	2-19	19-42	38-114	
Effectiveness		0.45%	5.32%	16.22%	45.41%	

### PROVEN SAFETY

No serious adverse reactions were reported during testing of Atrevia® XR <sup>(4)</sup>.

Observed Reactions						
Vomiting	Loss of appetite	Diarrhea	Lethargy	Polydipsia	Flatulence	Total
2	0	1	1	1	0	5
0.00%	0.00%	0.27%	0.27%	0.27%	0.00%	1.36%

# LEARN MORE ABOUT OUR SUPERCHEWS™



Exclusive technology developed by Agrovet Market for the production of chewable tablets. Learn more about the benefits of SUPERCHEWS™.

### SOFT CONSISTENCY


Softer consistency compared to other products.

### ATTRACTIVE SMELL AND TASTE

Exclusive blend of flavorings, which masks the taste of the active ingredients.

### HIGH ACCEPTANCE

Studies support its high acceptance with a voluntary consumption of 98% in treated dogs.



### TOTAL DISINTEGRATION

Proprietary association of two synergistic disintegrants, facilitates disintegration of the tablets.

### CONVENIENCE

Easy administration in dogs with oral problems or reluctant to take medication.

### DIVERSITY

Tablets in different sizes according to weight range.



## ATREVIA® XR

Available in 1 unit box and 4 units box.


### BIBLIOGRAPHIC REFERENCES

- 1.- Chávez L. 2021. Evaluación del tiempo de inicio de actividad pulgicida de una formulación oral a base de fluralaner de aplicación trimestral en caninos.
- 2.- Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de dos formulaciones orales a base de fluralaner para el tratamiento y control de pulgas en caninos naturalmente infestados.
- 3.- Chávez L., Liao V. 2021. Evaluación de la palatabilidad de una tableta masticable a base de fluralaner de aplicación trimestral1 en caninos.
- 4.- Chávez L., Liao V. 2021. Evaluación de la seguridad de una formulación oral a base de fluralaner de aplicación trimestral en caninos.
- 5.- Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de dos formulaciones orales a base de fluralaner para el tratamiento y control de garrapatas en caninos naturalmente infestados.
- 6.- Chávez L., Liao V. 2021. Evaluación de la efectividad, tolerancia y residualidad de dos formulaciones orales a base de fluralaner para el tratamiento y control de ácaros y la reducción de sus signos clínicos en caninos.
- 7.- External references.

**NEW**

# ATREVIA®

FLURALANER



## INTRODUCING AN IRRÉSISTIBLE PROTECTION



### Recommend ATREVIA® XR now.

The new chewable tablet with an irresistible taste for three months of protection. The care that every doglover seeks for their pet.

+51 (1) 922 926 786

sales@agrovvetmarket.com

fluralaner.vet

Facebook/atrevia Instagram/atreviadogs



For more information about Atrevia® and its distribution network, go to: [petmedica.vet](http://petmedica.vet)

Av. Canadá 3798 - San Luis 15021. Lima - Perú

511 2 300 300

ATREVIA® IS A PRODUCT OF PETMEDICA®, THE COMPANION ANIMAL DIVISION OF AGROVET MARKET S.A.

